Jane de Lartigue, PhD

Articles

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

NRG1 Fusions Hold Promise as Pan-tumor Target

November 17th 2020

The identification of chromosomal rearrangements that result in oncogenic gene fusions ushered in the era of molecularly targeted therapies in oncology.

NEDD8 Emerges as a Novel Target in Hematologic Malignancies

October 8th 2020

Investigators are developing a new way to target a key oncogenic mechanism that may prove to be an effective anticancer strategy, particularly against hematologic malignancies.

Interest Builds for Targeting TIGIT Checkpoint

September 15th 2020

TIGIT, an inhibitory immune checkpoint that plays a central role in limiting antitumor responses, is attracting robust interest in the research community as a novel target for combination therapies across a range of cancer types, particularly solid tumors.

New Era for Targeting HER2 Beckons in Breast Cancer and Beyond

September 3rd 2020

Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types.

Fresh Approaches May Be Key to Unlocking OX40 Checkpoint

August 21st 2020

Considerable efforts have focused on developing agonists of costimulatory receptors, including OX40.

HRD Testing Heralds a New Biomarker, but Questions Linger

August 5th 2020

Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.

CLR 131 Leads a New Generation of Lipid-Based Cancer Drug Delivery Systems

July 19th 2020

A novel compound that uses abundant lipids in cancer cell membranes to deliver a radioisotope to the tumor environment shows early signs of efficacy in a range of B-cell malignancies.

New Strategies for Targeting CD38 in Multiple Myeloma Take Root

June 26th 2020

During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.

A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology

June 8th 2020

Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.

A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology

June 8th 2020

Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.

Hard-to-Target WNT Pathway Gets a Fresh Look in Oncology

May 19th 2020

Investigators continue to find innovative ways to attack the WNT pathway beyond targeting the major molecular players.

Agents Targeting ROS1 Gain Traction in NSCLC

May 1st 2020

The past 2 decades have been transformative for the treatment of non–small cell lung cancer; two-thirds of patients have been found to harbor molecular drivers, and a growing proportion of these are now targetable with FDA-approved drugs.

CML Research Aims to Improve a "Magic Bullet"

April 10th 2020

The approval of imatinib almost 20 years ago heralded the arrival of the targeted therapy era in oncology and thrust the ABL1 kinase into the limelight.

New Era of CDK Targeting Gets Rolling in Oncology

April 2nd 2020

Serving as gatekeepers at the entry to the cell cycle, CDK4 and CDK6 make ideal therapeutic targets to block the unchecked proliferation that is a hallmark of cancer cells.

AXL Kinase Becomes a Therapeutic Target in Its Own Right

March 17th 2020

Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.

BCMA Emerges as Hot Target in Myeloma, With CARs Leading the Way

March 5th 2020

Investigators have turned their attention to B-cell maturation antigen, which offers an ideal target for multiple myeloma therapy because of its restricted expression pattern.

Penn Investigator Sees Promises and Challenges in Myeloma Target

March 3rd 2020

Adam D. Cohen, MD, discusses the prospects for BCMA-targeting options in multiple myeloma.

Targeting TRAIL: A Long and Winding Road to Efficacy

February 25th 2020

Results from a first-in-human study into ABBV-621, a TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist, highlight the potential of focusing on TRAIL.

Expert: Raise the Bar for Diagnostic Tools in Oncology

February 24th 2020

Daniel F. Hayes, MD, discusses the potential of liquid biopsies in breast and other cancers and highlights some major challenges that keep these tests from wider use.

NEXT PAGE
PREVIOUS PAGE